Call for positions 

We offer: Cutting edge research projects and training with leading experts in the field of cell therapy; employment contract for three years with the benefits of the EU Marie Skłodowska-Curie program with the possibility of earning a doctoral degree (PhD or equivalent).

We seek: Excellent scientists with a Master's degree or equivalent in natural sciences or related disciplines (such as medicine or pharmacy); practical skills in modern laboratory work, preferentially combined with experience in animal experiments.

Your profile: You must be within your first four years of research experience after completion of your Master's degree or equivalent; you cannot hold a doctoral degree (except medical doctor) at the time of recruitment; you cannot have spent more than 12 months within the past 36 months in the country where the position you are applying for is located (mobility rule); you must be proficient in the English language both written and spoken (proof required).

Open positions:

• Project 1 (ESR1): Analysis of the influence of cytokine stimulation on ACT safety. In Germany, Munich, at Ludwig-Maximilians-Universität, supervised by Sebastian Kobold
• Project 2 (ESR2): Functional stimulation of T cells using artificial antigen scaffolds for T cell expansion. In Denmark, Copenhagen, at Danmarks Tekniske Universitet, supervised by Sine Reker Hadrup
• Project 3 (ESR3): Cytokine requirements for efficient expansion of peripheral blood and tumour-derived mucosal associated invariant T (MAIT) cells for ACT of cancer. In the Netherlands, Amsterdam, at Stichting VUMC, supervised by Tanja D. de Gruijl
• Project 4 (ESR4): Enhancing effector CD4 T cell polarization for ACT of cancer. In France, Dijon, at Institut National de la Santé et de la Recherche Médicale (INSERM), supervised by Lionel Apetoh
• Project 5 (ESR5): Generation of CAR T cells under minimally activating conditions. In Germany, Langen, at Paul-Ehrlich-Institut, Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel, supervised by Jessica Hartmann
• Project 6 (ESR6): Therapeutic potential of MerTK signalling in T cells for cancer therapy. In Denmark, Copenhagen, at Region Hovedstaden, University Hospital Herlev, supervised by Per Thor Straten
• Project 7 (ESR7): Improvement of tumour-infiltrating lymphocyte expansion for adoptive cell therapy. In Switzerland, Basel, at University of Basel, supervised by Heinz Läubli and Alfred Zippelius
• Project 8 (ESR8): Chimeric cytokine receptors for ACT of cancer. In Germany, Munich, at Ludwig-Maximilians-Universität, supervised by Sebastian Kobold
• Project 9 (ESR9): Designer cytokine receptors for ACT of cancer. In Switzerland, Zurich, at Roche Glycart AG, Roche Innovation Center Zurich, supervised by Christian Klein
• Project 10 (ESR10): Evaluation of strategies to enhance the efficacy of tumour infiltrating lymphocyte (TIL) therapy. In Great Britain, Manchester, at Instil Bio, team lead by Robert Hawkins with the supervisory team: Richard Edmondson, Professor of Gynaecological Oncology, University of Manchester; Anne Armstrong, Consultant/Senior Lecturer in Medical Oncology, University of Manchester/Christie Hospital; Gray Kueberuwa, Director of Research, Instil Bio UK and Jamie Honeychurch, Senior Lecturer, University of Manchester
• Project 11 (ESR11): Impact of the gut microbiome in maintenance or activation of ACT in cancer. In France, Paris, at Communauté d’universités et d’établissements Université Paris Saclay, supervised by Laurence Zitvogel
• Project 12 (ESR12): Metabolic reprograming of adoptively transferred T cells by tumour-derived cytokine networks. In Germany, Munich, at Ludwig-Maximilians-Universität, supervised by Sebastian Theurich and Michael von Bergwelt
• Project 13 (ESR13): Development of novel analytical models to study and improve CAR T cell response in pancreatic tumour-microenvironment. In Germany, Bergisch Gladbach, at Miltenyi Biotec GmbH, supervised by Andrew Kaiser
• Project 14 (ESR14): β2-adrenergic receptor signalling in T cell function. In Denmark, Copenhagen, at Region Hovedstaden, University Hospital Herlev, supervised by Per Thor Straten
• Project 15 (ESR15): Targeting immune receptor SLAMF6 in transferred T lymphocytes for improved T cell therapies. In Israel, Jerusalem, Hadassah Medical Organization, supervised by Michal Lotem.